Clinical Trial Update: Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating TOOKAD (VTP) vs active surveillance for intermediate-risk localized prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Localized Prostate Cancer

Drugs mentioned

• TOOKAD (padeliparvovec? (Note: TOOKAD is verteporfin-based vascular-targeted photodynamic therapy).)

Snippet

Sponsor: Steba Biotech S.A. | Conditions: Localized Prostate Cancer | Phase 3 | Status: WITHDRAWN